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Background: Exosomes are membranous nanovesicles secreted into the extracellular milieu by diverse cell types.
Exosomes facilitate intercellular communication, modulate cellular pheno/genotype, and regulate microbial
pathogenesis. Although human semen contains exosomes, their role in regulating infection with viruses that are
sexually transmitted remains unknown. In this study, we used semen exosomes purified from healthy human
donors to evaluate the role of exosomes on the infectivity of different strains of HIV-1 in a variety of cell lines.
Results: We show that human semen contains a heterologous population of exosomes, enriched in mRNA
encoding tetraspanin exosomal markers and various antiviral factors. Semen exosomes are internalized by recipient
cells and upon internalization, inhibit replication of a broad array of HIV-1 strains. Remarkably, the anti-HIV-1 activity of
semen exosomes is specific to retroviruses because semen exosomes blocked replication of the murine AIDS (mAIDS)
virus complex (LP-BM5). However, exosomes from blood had no effect on HIV-1 or LP-BM5 replication. Additionally,
semen and blood exosomes had no effect on replication of herpes simplex virus; types 1 and 2 (HSV1 and HSV2).
Mechanistic studies indicate that semen exosomes exert a post-entry block on HIV-1 replication by orchestrating
deleterious effects on particle-associated reverse transcriptase activity and infectivity.
Conclusions: These illuminating findings i) improve our knowledge of the cargo of semen exosomes, ii) reveal that
semen exosomes possess anti-retroviral activity, and iii) suggest that semen exosome-mediated inhibition of HIV-1
replication may provide novel opportunities for the development of new therapeutics for HIV-1.
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Exosomes are endogenous carriers of genetic cargo [1,2]
and they can transfer their cargo to recipient target cells
[3]. Exosomes are released by a variety of cell types and
have been isolated from diverse biological fluids, such as
blood plasma [4], urine [5], saliva [6], breast milk [7,8],
bronchoalveolar lavage fluid [8], and seminal plasma [9].
Human semen contains a heterogenous population of
membranous nanovesicles produced by tissues of the
male genital tract (MGT) [10]. Collectively, the diverse
array of semen-derived nanovesicles is most often
termed prostasomes. Owing to the fact that these nano-
vesicles arise from diverse cell types within the MGT, it
is more appropriate to refer to them as nanovesicles or* Correspondence: chioma-okeoma@uiowa.edu
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unless otherwise stated.exosomes. Due to their endosomal origin, exosomes are
endowed with a repertoire of host proteins, including
tetraspannins (CD9, CD63, and CD81) [11,12], miRNAs,
and mRNAs [13]. The RNA “cargo” of exosomes may be
significantly different from that of the originating paren-
tal cell content [14-16].
Exosomes from different origins are internalized by
cells [17] where they may mediate intercellular commu-
nication, immunoregulatory effects, and regulation of
microbial pathogenesis [18,19]. The ability of liver non-
parenchymal cell derived exosomes to modulate host
response against viral infection was previously suggested
for hepatitis B virus-infected hepatocytes [19]. Semen-
derived nanovesicles, hereafter referred to as semen
exosomes (SE), have been implicated in varied processes
relating to spermatozoa function and protection in the
vaginal milieu [20], but their role in viral infectivity has
not previously been demonstrated. It is thus conceivable
that the role of exosomes could be deduced from theirl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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block replication of sexually transmitted pathogens, such
as HIV-1.
HIV-1 transmission worldwide primarily occurs through
sexual contact and semen is the primary vector [21]. How-
ever, sexual transmission of HIV-1 requires a high number
of exposures [22,23]. It is known that post-coitus,
exposure of the female reproductive tract (FRT) to semen
results in immunomodulatory events that influence the
outcome of HIV-1 replication within the genital mucosa,
indicating that semen contains factors that may enhance
or abate HIV-1 infection [24-27].
Here we study the role of SE in HIV-1 replication. We
show that SE is internalized by recipient cells and upon
internalization SE blocks HIV-1 replication. SE-mediatedFigure 1 Characteristics of human semen exosomes. (A) Fluorescence-
with α-MHC-II antibody coated latex beads (4 μm) and stained for CD63 (L
antibody is represented by black histograms. (B) Left, transmission electron
CD63 (α-CD63) and detected by 6 nm gold-labeled secondary antibody (ar
and counterstained with 10 nm gold-labeled secondary antibody. Calnexin
protein extracts, stained for CD63, Calnexin, and GAPDH. Pooled SE populatio
(F) SE protein concentrations from different donors range between 5.3 – 6.8 minhibition of virus replication occurred post-entry and in-
volves impairment of viral RNA reverse transcription. Thus,
our data identify exosomes from semen as a critical fac-
tor that may reduce efficacy of HIV-1 transmission and
highlight a unique opportunity for additional studies on
the cargo composition and function of semen exosomes.
Results
Human semen contains exosomes loaded with proteins
and functional mRNA
FACS, TEM, and immunoblot analysis revealed that SE
is enriched in tetraspanin proteins CD63 and CD81, but
devoid of contaminating endoplasmic reticulum-derived
marker calnexin (Figure 1A, B and C), suggesting that
we have pure populations of exosomes. Structurally, weactivated cell sorting (FACS) analysis of pooled (n =20) SE incubated
eft, red histogram) and CD81 (Right, red histogram). Isotype control
microscopy (TEM) of pooled (n =20) semen exosome (SE) stained for
row). Right, TEM of pooled (n =20) SE stained for Calnexin (α- Calnexin)
was not detected. (C) Western blot of SE (n =5) and paired spermatozoa
n (n =89) were categorized based on (D) size and (E) electron density.
g/ml of semen.
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with respect to size [28] and electron density [29]
(Figure 1D and E). The protein concentrations within
SE are similar amongst donors and range between
5.3 – 6.8 mg/ml of semen (Figure 1F). Additional
characterization reveals that SE contains diverse RNA
species, including small RNA and mRNA (Figure 2A),
supporting a previous report [30]. The ability to
synthesize complimentary RNA capable of sustaining
PCR amplification of tetraspanins (Figure 2B) and vari-
ous antiviral factors, such as host restriction factors
(HRFs); that block replication of diverse retroviruses
(Figure 2C) demonstrates that SE contains polyadeny-
lated RNA capable of supporting gene expression. The
presence of HRF mRNA, including Apobec3 (A3) and
BST-2 in SE is intriguing since exosome-mediated
transfer of RNA from donor to recipient cells results in
functional RNA-related biological effects in the recipi-
ent cells [15,31].
Semen exosomes inhibit HIV-1 replication
To assess the role of SE in HIV-1 replication, we first
evaluated whether SE is internalized by target cells.
Uptake of PKH67Green-labeled SE by HIV-1 target cells,Figure 2 Human semen contains exosomes loaded with coding mRNA
different RNA species. Arrows show peaks for 18 s, 28 s, and the horizontal
and CD63) mRNA and host restriction factors (HRFs) mRNA present in paire
donors. GAPDH is present in SE and spermatozoa and was used as loadingTZM-bl was evident within 3 h of exposure of TZM-bl to
SE; with increased uptake observed at 24 h post-exposure
(Figure 3A). We further determined that SE has no effect
on recipient TZM-bl cell viability because cytotoxicity was
not observed upon exposure of cells to SE, even at con-
centrations as high as 1000 μg/ml (data not shown).
Analysis of HIV-1 Tat-dependent luminescence in the
presence of SE showed marked suppression of HIV-1
replication by various donor SE that were pre-incubated
with HIV-1 in comparison to control cells exposed to
HIV-1 that was pre-incubated with PBS alone (Figure 3B).
Pooled donor SE (n =20) with concentrations ranging
from 0.7 – 400 μg/ml diminished HIV-1 infectivity in a
dose-dependent manner (Figure 3C) and SE (100 μg/ml)
potently blocked a wide range of HIV-1 viral inoculum
(Figure 3D). While pre-incubating SE with HIV-1 for 1 h
at 37°C resulted in the most efficacious inhibition
(Figure 3B-D), simultaneous addition of SE and virus
to cells, or pre-treatment of cells with SE for various
times prior to viral challenge partially protected cells
against HIV-1 in a time dependent manner (Figure 3E).
In addition, SE conferred partial protection when
added to TZM-bl cells at different time points after
viral challenge (Figure 3F).. (A) RNA analysis with the Bioanalyzer revealed that SE contains
line represents small RNA. (B and C) PCR analysis of tetraspanin (CD9
d SE and spermatozoa samples. Numbers 1 to 5 represent different
control.
Figure 3 Semen exosomes inhibit HIV-1 replication. (A) TZM-bl cells were evaluated for cellular uptake of green fluorochrome-labelled SE by
FACS. PKH67Green-labelled PBS (gray histogram) was used as control. (B) TZM-bl indicator cells challenged with HIV-1NL4.3 pre-incubated with PBS
Vehicle or with 100 μg/ml individual donor SE, or pooled (n =20) SE. Infectivity was determined by luminescence output with control set
at 100% infection. (C) TZM-bl indicator cells challenged with HIV-1NL4.3 pre-incubated with increasing concentrations (0–400 μg/ml) of SE
and analyzed for infectivity by luminescence output. (D) TZM-bl cells were challenged with 100 μg/ml of SE pre-incubated with increasing
concentrations (1 – 500 ng/ml p24) of HIV-1NL4.3. Infectivity was determined by luminescence output. (E) HIV-1NL4.3 was pre-incubated for
1 h with vehicle (gray bar, vehicle) or with SE (SE), or added simultaneously with SE (0 h), or added prior (1 h, 2 h, 3 h, and 24 h) to HIV-1 chal-
lenge. Infectivity on TZM-bl cells was measured by luminescence emission with vehicle set at 100% infection. (F) HIV-1NL4.3 was pre-incubated
for 1 h with vehicle (gray bar, vehicle) or with SE (SE), or added directly to TZM-bl indicator cells at 1 h or 2 h post-infection. Infectivity was mea-
sured by luminescence emission with vehicle set at 100%. Student’s t test was used for all samples, significance was taken at *P <0.05,
**P <0.02. Experiments were repeated at least 3 times with similar results.
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cell types
To determine whether SE is capable of blocking HIV-1
replication in cells with physiologic relevance to HIV-1
replication, we quantified HIV-1 proviral DNA and viral
RNA from different cell types in the presence or
absence of SE. This experiment also assessed cell type
specific responses to SE-mediated inhibition of HIV-1.
Control cells were pre-treated with the reverse transcrip-
tion inhibitor AZT prior to infection. Levels of HIV-1
DNA (Figure 4A-F) and HIV-1 RNA (Figure 4H) revealed
that SE potently diminished HIV-1 infectivity in U937 andTHP-1 monocytic cell lines (Figure 4A,B and H) as well as
in various T cell lines, including CEM (Figure 4C and H),
Jurkat (Figure 4D and H), SupT1 (Figure 4E and H) and
PM1 (Figure 4F and H). Importantly, SE significantly
restricted HIV-1 replication in primary peripheral blood
lymphocytes (PBL) in a donor-dependent manner as shown
by significant reduction in levels of HIV-1 DNA (Figure 4G)
and HIV-1 RNA (Figure 4I). Furthermore, SE abrogated in-
tegration of viral DNA into the host chromosomal DNA
(Figure 4J). Indeed, SE inhibited HIV-1 replication and
integration in all cell lines queried. However, we observed
modest cell type-dependent responses. Of note, SE-
Figure 4 Cell type- and virus strain- independent restriction of HIV-1 replication by semen exosomes. (A and B) Monocytic cell lines (A)
U937 and (B) THP1; (C to F) T lymphocyte cell lines; (C) Rev-CEM, (D) JURKAT, (E) SupT1, (F) PM1, and (G) PBL (from 3 different healthy donors)
pretreated ± AZT for 2 h were exposed to HIV-1SF-162 or HIV-1NL4-3 pre-incubated with PBS or SE for 1 h. Total DNA isolated from cells was examined for
levels of HIV-1 Gag DNA 24 h later by qPCR. (H) U937, THP1, Rev-CEM, JURKAT, SupT1, and PM1 were exposed to HIV-1SF-162 or HIV-1NL4-3 pre-incubated
with PBS or SE for 1 h. Total RNA was examined for levels of HIV-1 Gag RNA 24 h later by RT-qPCR. (I) PBL from 3 healthy donors were pretreated ± AZT
for 2 h and exposed to HIV-1NL4-3 pre-incubated with PBS or SE. Infectivity was assessed by qPCR and RT-qPCR for detection of HIV-1 Gag DNA or RNA
respectively. (J) Total DNA was examined for integrated HIV-1 DNA in U937 cells exposed to HIV-1SF-162 or SupT1 cells exposed to HIV-1NL4-3 in the presence
or absence of SE or AZT by Alu-PCR. (K) TZM-bl cells exposed to R5-monotropic clade B (SF162) or X4-monotropic clade B (IIIB and U1) pre-incubated with
PBS or SE. HIV-1 pre-incubated with PBS was set at 1. (L) TZM-bl cells exposed to transmitted/founder (T/F) molecular infectious clones (REJO and CH162)
of HIV-1 pre-incubated with PBS or SE were examined for infectivity by luminescence output. HIV-1 pre-incubated with PBS was set at 1. **P < 0.02 and
Student's t test was used for all samples. Data are expressed as mean ± SD and presented as fold change of vehicle. Experiments were repeated at least
three times with similar results.
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inhibition imposed by AZT (especially in PBLs [Figure 4G];
and U937 cells [Figure 4A and J]); although some cell
type-dependent variability was also observed.
Lab-adapted and clinical isolates of HIV-1 are susceptible
to SE inhibition
Compared to HIV-1 alone, SE significantly compromised
replication of lab-adapted and transmitted/founder (T/F)
viruses as indicated by HIV-1 Tat-dependent lumines-
cence output (Figure 4K and L). These results signify
that the anti-HIV-1 effect of SE extended to different
R5- and X4-tropic lab-adapted and transmitted/founder
(T/F) viruses regardless of tropism.
Inhibition of retrovirus replication is specific to semen
exosomes
SE is internalized by target TZM-bl cells (Figure 3A)
and we show that exosomes from blood serum (BE) are
also internalized (Figure 5A). Unlike SE that was inter-
nalized as early as 3 h post addition to cells, BE was notFigure 5 HIV-1 is not sensitive to blood exosomes. (A) TZM-bl cells we
serum exosome (BE) by FACS. PKH67Green-labelled PBS (gray histogram) was
present in BE donor samples. Numbers 1 to 4 represent different donors. GAP
cells challenged with HIV-1NL4-3 pre-incubated with PBS or with 100 μg/ml do
control set at 100% infection. (D) TZM-bl cells exposed to R5- and X4-tropic
X4-monotropic clade B (IIIB and U1) pre-incubated with PBS or BE. Infectivity w
100%. (E) TZM-bl cells exposed to transmitted founder (T/F) molecular infectio
examined for infectivity by luminescence output. Differences between treatm
times with similar results.internalized by TZM-bl cells at 3 h. However, BE intern-
alization was evident 24 h later (Figure 5A). Like SE, BE
also contains polyadenylated RNA capable of support-
ing gene expression as evidenced by the presence of
HRF transcripts (Figure 5B). It is worth mentioning that
similar to SE (Figure 2C), there is donor-dependent vari-
ability in BE content of HRFs (Figure 5B). To determine
whether SE-mediated block on HIV-1 replication can be
achieved with BE, TZM-bl cells were exposed to HIV-
1NL4.3 that had been pre-incubated with vehicle or BE.
In comparison to SE (Figure 4), BE-treated viruses
retained infectivity (Figure 5C). Level of infectivity ob-
served in the presence of BE paralleled that seen with
HIV-1 alone (Figure 5C), corroborating a previous
report [32]. A similar trend was observed when BE was
pre-incubated with various lab-adapted (Figure 5C-D)
and T/F viruses (Figure 5E).
Since SE but not BE blocked HIV-1 replication, we
assessed whether SE and/or BE could inhibit replication
of viruses other than HIV-1. We pre-incubated SE or BE
with herpes simplex viruses (HSV) -1 and −2 which arere evaluated for cellular uptake of green fluorochrome-labelled blood
used as control. (B) PCR analysis of host restriction factor (HRF) mRNA
DH is present in BE and was used as loading control. (C) TZM-bl indicator
nor (n =3) BE. Infectivity was determined by luminescence output with
lab-adapted HIV-1 isolates, including R5-monotropic clade B (SF162),
as assessed by luminescence expression. Vehicle infectivity was set at
us clones (REJO and CH162) of HIV-1 pre-incubated with PBS or BE were
ents were not significant (ns). Experiments were repeated at least three
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replication by plaque assay on HEp-2 cells reveals that
SE and BE had no effect on HSV replication (Figure 6A
and B). Additionally, pretreatment of HEp-2 cells with
SE or BE prior to infection had no effect on herpesvirus
plaque formation (Figure 6C and D). These data indicate
that exosomes from either semen or blood are unable to
inhibit HSV replication in cells.
To examine whether SE blocks replication of another
sexually transmitted retrovirus [33], we pre-incubated SE
with the LP-BM5 MLV murine AIDS virus complex or
PBS and subsequently challenged naïve murine spleno-
cytes with LP-BM5 pre-incubated with SE or PBS. Ana-
lysis of LP-BM5 MLV replication by RT-qPCR reveals that
SE suppressed LP-BM5 proviral DNA compared to the
vehicle control (Figure 6E). These data indicate that the
anti-viral effect of SE is perhaps an intrinsic feature of SE
on sexually transmitted retroviruses but not herpesviruses.
Semen exosomes do not impair the concentration of
HIV-1 that enters target cells
To identify the mechanism of retroviral suppression by
SE, we used HIV-1 infection of TZM-bl target cells toFigure 6 HSV −1 and HSV −2 are refractory to the antiviral activity of
cells was determined by counting plaque forming units (PFU) two days po
at 37°C with PBS vehicle (gray bar), 100 μg/ml semen exosomes or 100 μg
unit (PFU) per ml. (C and D) HEp-2 cells were preincubated at 37°C for 1 h
followed by challenge with HSV-1 or HSV-2 (MOI =5) at 37°C for 1 h. Viral r
and titered on Vero cells for determination of virus titre by plaque assay. D
Student’s t test was used for all samples; significance was taken at P ≤0.05.
similar results. (E) Murine splenocytes are susceptible to SE-mediated inhib
with LP-BM5 pre-incubated with vehicle or SE. 96 h post challenge, total D
detection of proviral DNA. Results were normalized for GAPDH. Data are mean
test was used for all samples. Experiments were repeated at least three timesassess whether SE impairs the concentration of HIV-1
that enters cells. For this purpose, TZM-bl exposed to
HIV-1 in the presence or absence of SE for 3 h were
washed and trypsinized [34] to remove input virus prior
to cell lysis and analysis of intracellular HIV-1 p24
concentration using p24 antigen ELISA. We found that
equivalent concentrations of HIV-1 entered cells in the
presence and absence of SE (Figure 7A). In parallel,
reverse transcriptase (RT) activity in these cells at the 3 h
time point suggested that SE did not compromise viral
fitness post entry as measured by RT activity (Figure 7B).
These results are consistent with SE-mediated post-entry
block on HIV-1 infectivity.
Semen exosomes compromise intravirion reverse
transcriptase activity
Because SE had no effect on the concentration of virus
that entered target cells at 3 h post infection (Figure 7A
and B) and SE compromised proviral DNA integration
and gene expression at 24 h post infection (Figures 4), we
assessed the effect of SE on the concentration and fitness
of progeny virions generated 24 h following infection.
Surprisingly, the concentration of progeny generatedsemen exosomes. (A and B) Infectivity of HSV-1 or HSV-2 on HEp-2
st infection with 2 X 105 PFU of HSV-1 or HSV-2 pre incubated for 1 h
/ml blood exosomes (white bar). Virus titre is shown as particle forming
with PBS vehicle (gray bar), 100 μg/ml SE or 100 μg/ml BE (white bar)
eplication was allowed to ensue for 18 h. Progeny virus was collected
ata are mean ± SD and are reported as plaque forming units (PFU).
ns = not significant. Experiments were repeated at least 3 times with
ition of LP-BM5 replication ex vivo: Naïve splenocytes were infected
NA was isolated and used to evaluate viral load by quantitative PCR
± SD expressed as fold change of vehicle set at 1. *P <0.02, Student’s t
with similar results.
Figure 7 Post-entry effect of semen exosomes on HIV infectivity. Intracellular HIV-1NL4.3 (A) p24 ELISA and (B) RT activity in TZM-bl cells 3 h
post-challenge. Data ± SD are plotted as fold change of vehicle set at 1. (C) Cell free supernatant progeny of HIV-1NL4-3 produced from TZM-bl 24
h post-challenge depicting levels of p24 Gag as assessed by p24 ELISA. (D) Intravirion RT activity of HIV-1 progeny produced from TZM-bl 24 h
post-infection. Data ± SD are expressed as fold change of vehicle set at 1 for all graphs. (E) Intravirion Gag RNA expression in cell-free supernatant
progeny of HIV-1NL4-3 produced from TZM-bl reporter cells 24 h post-challenge with HIV-1 pre-incubated with vehicle or SE. Total progeny viral
RNA was isolated from cell-free supernatant, converted to cDNA and examined for HIV-1 Gag expression by RT-qPCR. Results were normalized for
GAPDH. Data ± SD are expressed as fold change of vehicle set at 1. (F) Secondary infectivity of HIV-1 viral progeny isolated from cell free supernatant
of TZM-bl reporter cells 24 h post-challenge with HIV-1 pre incubated with vehicle or SE. Input was normalized for p24, added to fresh TZM-bl reporter
cells and infectivity was evaluated by luminescence output 24 h post-challenge. Data ± SD are shown as % secondary infectivity with progeny
generated in the presence of vehicle set at 100%. For panels A-F, ns = not significant, **P < 0.02, Student's t test was used for all samples. (G and H)
Immunoblot using 30 μg of viral protein (progeny) or cellular protein from TZM-bl cells challenged for 24 h with HIV-1NL4-3 ±SE and probed with
antibody against HIV-1 RT or p24 Gag to detect (G) intravirion or (H) intracellular HIV-1 RT and p24 Gag proteins.
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equivalent at 24 h post infection as determined by p24
ELISA (Figure 7C). However, intravirion RT activity, a
measure of viral fitness, was reduced in progeny produced
at 24 h post infection in the presence of SE (Figure 7D).
Additionally, the effect of SE on HIV-1 RNA incorporatedinto nascent progeny virions 24 h post infection was ex-
amined by qPCR of Gag RNA expression. Progeny gener-
ated in the presence of SE contained ≤50% Gag RNA
compared to vehicle control (Figure 7E).
Because both progeny RT and RNA were impaired by
SE, we assessed progeny fitness by infecting TZM-bl
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24 h infection with HIV-1 ± SE. Progeny generated in the
presence of SE demonstrated a greater than 50% reduction
in secondary infectivity, revealing that SE diminished
replication of HIV-1 by compromising the fitness of
progeny virions (Figure 7F).Semen exosomes alter HIV-1 RT protein composition
To further probe the effect of SE on HIV-1 RT, we eval-
uated intravirion RT protein composition by Western
blotting. We found differences in the ratios of RT
heterodimer (p51 and p66) but not p24 within progeny
virions generated 24 h post infection in the presence and
absence of SE.
Further analysis revealed that when normalized to p24
and compared to vehicle control, SE decreased intra-
virion p66 protein and had no effect on p51 protein
(Figure 7G; blot and bars―compare the solid and
stripped bars). Intracellularly, SE increased p51 and had
no effect on p66 (Figure 7H; blot and bars, compare the
solid and stripped bars). Interestingly, progeny virion
and cellular p24 Gag levels were equivalent in the pres-
ence and absence of SE both in the progeny and cell
extract; an indication that i) SE may not have affected
Gag incorporation and processing (Figure 7G and H,
and bars); and ii) same concentration of HIV-1 is generated
in the presence or absence of SE.Discussion
Exosomes deliver their cargo to recipient cells and sub-
sequently modulate host cell function. The mechanisms
involved in exosomal modulation of various intracellular
events are only beginning to be understood but clearly
involve internalization and cargo delivery [14-19]. Indeed,
exosomes from different sources possess antiviral activ-
ities. This is evident in the case of exosomal delivery of
antiviral IFNα to HBV infected hepatocytes [19] and
blockade of HIV-1 infection of dendritic cells by breast
milk exosomes [32]. The present study aimed to provide
answers as to whether exosomes from semen (i) are
internalized by target cells and (ii) possess antiviral
activity against viruses transmitted via semen.
We found that human semen exosomes (SE) are effi-
ciently internalized by target cells as early as 3 hours
after exposure of cells to SE. Importantly, SE restricted
replication of a wide range of HIV-1 strains and the mur-
ine AIDS virus complex LP-BM5. Inhibition of retrovirus
replication by SE is specific as exosomes from blood (BE)
had no effect on these viruses. Moreover, SE did not
restrict replication of HSV types −1 and −2, demon-
strating that the SE antiviral effect is specific to retrovi-
ruses. The anti-HIV-1 effect of SE appeared to occur
after virus entry.Although equivalent amounts of HIV-1 (as demonstrated
by HIV-1 p24 Gag levels) entered host cells in the presence
and absence of SE at 3 h post infection, later in the
infection process p24 Gag levels remained unchanged
while viral RT activity was drastically reduced in HIV-1
progeny generated in the presence of SE. Unlike p24,
which measures total virus production, including in-
fectious, noninfectious, and decaying viral particles
and only requires the presence of an intact epitope in
the capsid/p55 Gag, RT is the best surrogate measure
of infectious virus as it measures a specific enzyme
function [35]. Therefore, our data suggests that SE
impairs HIV-1 DNA and RNA expression and pro-
geny infectivity but has no effect on the amount of
viral progeny produced from infected cells. Although
it is yet to be determined how and why Gag protein
level remained unchanged while RNA level is dimin-
ished by SE, it is worth noting that others have ob-
served similar trends in viral nucleic acid and cognate
protein expression. It was previously demonstrated
that HIV-1 Gag protein expression can be rescued
while Gag mRNA expression is depleted [36], and
that steady state Gag protein is sufficient to be incor-
porated into progeny virions in the absence of de
novo Gag synthesis [37].
The molecular mechanism for the antiretroviral effect
of SE on HIV-1 replication is not fully understood but
appears to involve alteration in intravirion RT activity
and protein composition. The HIV-1 RT is a hetero-
dimer composed of p66 and p51 kDa polypeptides.
Appropriate association of these subunits is required
for RT enzymatic activity because monomeric subunits
lack polymerase activity [38,39]. In our study, p66 RT
subunit was absent from virions generated in the pres-
ence of SE. Additionally, SE-generated progeny viruses
contain less Gag RNA but p24 did not change.
The observation that HRFs mRNAs, such as Apo-
bec3 are part of SE cargo is intriguing, as Apobec3 is a
potent antiretroviral [33,40-44]. Apobec3 mediates
inhibition of retroviruses by deamination-dependent
and independent mechanisms, the later involving in-
hibition of RT by Apobec3 [43,45-47]. Consistent with
this idea, our data show that SE drastically decreased
HIV-1 RT activity. While a previous report showed that
exosomal Apobec3G released by H9 T lymphocyte
cells blocked HIV-1 infection [18], the role of Apobec3
or other HRFs mRNA enwrapped in SE is yet to be
determined.
Follow up studies are required to gain understanding
of the exact mechanism of SE-mediated HIV-1 inhib-
ition. It is also important to determine whether, like SE
from healthy donors, SE from HIV-1 positive individuals
contains antiviral mRNA cargo and suppresses HIV-1
infectivity.
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Our findings suggest that a major function of SE is to
counteract HIV-1 replication by impairing viral infectiv-
ity through the generation of progeny viruses with defect
in RT. The fact that HIV-1 is susceptible to antiviral
effects of SE suggests a point of vulnerability for the
virus that could be therapeutically exploited. Thus, this
study serves as a paradigm for understanding the func-
tions of exosomes secreted into human semen.
Methods
Ethics statement
This study involves the use of existing human specimens
(semen, serum, and PBLs) and therefore is not human
subjects’ research. Barthelemy Konan and Dr. Melanie
Freeman of the Reproductive Specialty Laboratory of
Middle Tennessee, Nashville provided de-identified
samples of human semen. These samples were dis-
carded from routine examinations and not linked to
any identifiers. Healthy HIV-1-negative subjects were
invited to participate in the study. Following written
informed consent, blood was obtained for exosome and
PBL isolations. This study was approved by the Univer-
sity of Iowa Institutional Review Board.
Experiments involving the use of mice were performed
in accordance to NIH guidelines, the Animal Welfare
Act, and US federal law. Experiments were approved by
the University of Iowa Animal Care and Use Committee
(IACUC). All mice were housed according to the policies
of the Institutional Animal Care and Use Committee of
the University of Iowa.
Acquisition of human semen
Semen samples were collected by dry manual stimula-
tion and ejaculation into sterile polypropylene tubes.
Samples were stored at room temperature for 30 min to
promote liquefaction and then centrifuged for 10 min at
1000 × g at 4°C to pellet spermatozoa. Spermatozoa-
containing pellets were either discarded or used as
paired samples. Where indicated, seminal plasma sam-
ples were pooled. Seminal plasma samples were stored
at -80°C until required for exosome purification.
Exosome purification
ExoQuick
Seminal plasma samples were thawed and centrifuged at
2000 × g for 15 min followed by centrifugation at 10,000 × g
for 30 min to pellet cellular debris. ExoQuick (SBI)
exosome precipitation reagent was used according to
the manufacturer’s instructions. Briefly, ExoQuick was
added at a ratio of 4:1 (seminal plasma/ExoQuick)
followed by resuspension by inversion and incubation
at 4°C overnight. The seminal plasma/ExoQuick mixture
was centrifuged at 1500 × g for 30 minutes. Supernatantwas removed and the exosome pellet in ExoQuick was
washed in PBS three times with centrifugation at 1500 × g
for 15 minutes, diluted 50% in PBS, aliquoted, quantified
by the Bradford method and stored at -80°C until use.
Exosomes from blood serum were also purified with
ExoQuick. While the polymer-based ExoQuick precipitation
solution is gaining popularity as a technically facile and
relatively less time consuming method for exosome
purification [48-50], we also performed our experimen-
tation with exosomes purified via more conventional
sucrose gradient differential ultracentrifugation methods
as previously described [18,51].
Sucrose gradient differential ultracentrifugation
Briefly, clarified seminal plasma was diluted 50% in PBS,
0.45 μm filtered and ultracentrifuged at 100,000 × g to
pellet exosomes using a SW41Ti rotor. Exosome pellets
were washed by resuspension in PBS and ultracentrifu-
gation at 100,000 × g for 1 h. Pellets were resuspended
in PBS, mixed with 2.5 M/L sucrose, placed on the bot-
tom of SW41Ti ultracentrifuge tubes and overlaid with
2 M/L followed by 0.25 M/L sucrose. After 16 h of ultra-
centrifugation at 100,000 × g (SW41Ti rotor, Beckman
Coulter), exosomes were collected from the main band
at the 2 M/L and 0.25 M/L interface, resuspended in
PBS and pelleted by ultracentrifugation for 30 min at
100,000 × g. The exosome pellets were resuspended in a
volume of sterile PBS equivalent to the original volume
of undiluted seminal plasma, aliquoted, protein concen-
tration quantified by the Bradford method (Bio-Rad),
and stored at −80°C until use. We determined that the
method of purification did not alter the ability of SE to
inhibit HIV replication.
Viruses
HIV-1pNL4.3 was obtained from the NIH AIDS Reagent
Program and expanded by transfecting HEK 293 cells
using Lipofectamine according to the manufacturer’s
instructions (Invitrogen). U1 virus stock was produced
from U937 cells chronically infected with U1 R5-tropic
HIV-1 obtained from the NIH AIDS Reagent Program.
The U1/HIV-1 cells were induced for 48 h using 100 ng/ml
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich).
Thereafter, supernatants were collected and centrifuged
at 1500 × g for 5 min to remove cellular debris then
0.45 μm filtered. HIV-1 was purified from culture
supernatants of infected cells by ultracentrifugation at
30,000 rpm for 2 h through a 20% sucrose cushion,
as previously described [52]. Viral pellets were resus-
pended in RPMI and stored at −80°C until use. Trans-
mitted/founder HIV-1 infectious molecular clones,
REJO and CH162 [53] in addition to pSF162 plasmid
were provided by Dr. Wendy Maury of the University of
Iowa and produced by PEI transfection of HEK 293 cells.
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tion over a sucrose cushion as described above. All puri-
fied and pelleted viral stocks were treated with DNAse,
resuspended in RPMI with 10% exosome-free fetal calf
serum, aliquoted, and stored at −80°C until use. Purified
viral stock titres were established using the Lentivirus-
Associated p24 ELISA Kit (Cell Biolabs). Luciferase as-
says were performed with stock virus infected TZM-bl
cells to determine virus replication and titres using a
luciferase reporter gene assay system with extended-
glow light emission kinetics (Steady Glo Luciferase
Assay kit; Promega). LP-BM5 murine leukemia retro-
virus (MLV) was prepared from the supernatant of a
7 day culture of the G6 clone of chronically infected
SC-1 cells as previously described [33,54]. The proper-
ties and propagation of HSV-1 and HSV-2 have been
previously described [55,56].
Cells
The following cell lines were obtained through the NIH
AIDS Reagent Program: PM1, TZM-bl, Sup-T1, Rev-
CEM, H9, and U1/HIV-1. The U1/HIV-1 is a chronically
infected cell line derived from limiting dilution cloning of
U937 cells surviving acute infection with HIV-1LAI/IIIB.
The Jurkat T lymphocyte cell line and the HEK 293
human embryonic kidney cell line were obtained from
the American Tissue Culture Collection (ATCC). PM1,
Sup-T1, Rev-CEM, and Jurkat cells were maintained in
complete RPMI (cRPMI) 1640 (Gibco-BRL/Life Tech-
nologies) supplemented with 10% exosome depleted
FCS (HyClone), 100 U/ml penicillin, 100 μg/ml strepto-
mycin, sodium pyruvate and 0.3 mg/ml l-glutamine
(Invitrogen, Molecular Probes). TZM-bl and HEK 293
cells were maintained in complete DMEM (cDMEM,
Gibco-BRL/Life Technologies) supplemented with 10%
exosome free FCS, 100 U/ml penicillin, 100 μg/ml
streptomycin, sodium pyruvate and 0.3 mg/ml l-glu-
tamine. Peripheral blood mononuclear cells (PBMCs)
from several healthy anonymous blood donors were
isolated from whole human blood using Ficoll-Hypaque
density centrifugation according to the manufacturer’s
instruction (Sigma-Aldrich). Monocytes were depleted
from the PBMCs by adherence on gelatin-coated flasks
as previously described [57]. The remaining peripheral
blood leukocytes (PBLs) were propagated in cRPMI
1640 stimulated for 48 h with 5 μg/ml phytohemagglu-
tinin (PHA, Roche Applied Science). Stimulated PBLs
were washed with cRPMI and resuspended in fresh
medium with interleukin-2 (IL-2; 10 U/ml). After 48 h,
cells were used in experiments. SC1-G6 cells chronic-
ally infected with LP-BM5 (containing ecotropic, mink
cell focus-forming and defective viruses) were obtained
through the AIDS Research and Reference Reagent
Program, and maintained in cDMEM. HEp-2 cells andVero African green monkey kidney cells were from
ATCC and were maintained in cDMEM. All cells were
grown at 37°C with 5% CO2. Cell viability was assessed
by CellTiter-Glo® luminescent cell viability assay (Promega
Corporation).
Electron microscopy
Transmission electron microscopy was done as previ-
ously described [58,59]. Exosomes were fixed in 2% para-
formaldehyde and loaded onto formvar carbon coated
grids. Exosomes adhered to carbon grids were PBS
washed and immuno-stained with anti-CD63 antibody
(BD Biosciences) or anti-Calnexin (EMD Millipore) over-
night at 4°C. Grids were washed and incubated with 6 nm
gold conjugated secondary antibody (Sigma-Aldrich) for
1 h at room temperature. Exosomes were then fixed with
2.5% glutaraldehyde, washed, contrasted in 1% uranyl
acetate and imaged with a JEOL JEM 1230 transmission
electron microscope.
FACS analysis
4-μm diameter aldehyde/sulphate latex beads (Invitrogen,
Molecular Probes) were washed in MES buffer and incu-
bated with anti MHC-II MAb (provided by Dr. Nicholas
Zavazava of the University of Iowa) or mouse IgG1
(Sigma-Aldrich) at room temperature overnight with
gentle agitation. Exosomes (100 μg) were incubated at
4°C overnight with gentle agitation with 2 × 105 anti
MHC-II or mouse IgG1 coated latex beads. The reac-
tion was stopped by 30 minute incubation with 200 mM
glycine followed by three washes in FACS wash buffer
(PBS with 1% exosome depleted FCS). Exosomes coated
beads were then incubated with anti-CD63 conjugated to
PE (Biolegend), anti-CD81 conjugated to FITC (Biolegend)
or isotype control antibody for 1 h at room temperature
and washed three times in FACS buffer. The resulting
immunofluorescence was analysed by use of a FACSAria
flow cytometer (Becton Dickinson) and Flowjo analysis
software (TreeStar).
Western blot analysis
Western blot was performed as previously described
[42,60,61]. Briefly, for detection of CD63, calnexin and
GAPDH, exosome preparations and spermatozoal extracts
were lysed, resolved on a 12% SDS-PAGE, and stained
with anti-CD63 (BD Biosciences), anti-GAPDH, or anti-
Calnexin (EMD Millipore). The species-appropriate
IRDye secondary antibodies were used followed by de-
tection with the Odyssey Infrared Imaging System (LI-
COR Biosciences). For detection of HIV-1 p24 and RT,
monoclonal antibody to HIV-1 p24 (AG3.0) and anti-
RT antibody (cat#6195) all obtained from NIH AIDS
Reagent Program were used to probe immunoblot,
followed by detection with the species-appropriate IRDye
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Real-time quantitative PCR
Quantitation of newly synthesized HIV-1 DNA was per-
formed by Real-time quantitative PCR [40,43,60,62,63]
using the 7500 fast real time PCR System (Applied
Biosciences). Total DNA was extracted using the Wizard
SV Genomic DNA purification kit (Promega). DNA
concentration was determined spectrophotometrically
and predetermined DNA was used to quantify viral
cDNA intermediates using primers that amplify HIV-1
Gag [64]. Integration of HIV-1 proviral DNA was exam-
ined by nested PCR using genomic DNA isolated as
described above. The Alu sense and HIV-1 Gag antisense
primers were used for the first PCR and a predetermined
amount of this PCR product was then used as template
for nested PCR to detect HIV-1 LTR as previously
described [65,66]. Exosome and spermatozoal RNA
were isolated with Trizol RNA Reagent (AMRESCO)
and treated with DNase (Qiagen). A portion of RNA
was analyzed for RNA content and quality using Agilent
Bioanalyzer instrument (Agilent). Another portion of
RNA was subjected to cDNA synthesis (ABI) as previously
described [33,58,60,62]. RNA concentration and purity
were measured spectrophotometrically at 260/280 nm.
Using synthesized cDNA, sequence-specific primers were
used to amplify human CD9, CD63 and GAPDH while
TaqMan primer/probes were used to detect APOBEC3
family members and BST-2/Tetherin as previously
described [58,60,63]. PCR amplicons were visualized
with ethidium bromide (Invitrogen, Molecular Probes)
on 2% agarose gels in TAE buffer (Tris/EDTA/glacial
acetic acid). LP-BM5 viral RNA and proviral DNA were
determined as previously described [33,54]. Briefly, total
RNA and DNA were isolated using a ZR-Duet™ DNA/
RNA Mini Prep Kit (Zymo Research). Isolated RNA was
exposed to DNAse and subjected to cDNA synthesis
(ABI) as previously described [58-60,62,63]. Nucleic
acid concentration and purity were measured spectro-
photometrically at 260/280 nm. DNA and cDNA were
amplified with primers and probe specific to BM5eco
gag [33,54] and GAPDH using ABI 7500 FAST thermal
cycler (ABI).
In vitro exosome uptake
Exosomes were labeled in ultracentrifuge tubes at room
temperature using the PKH67Green fluorescent kit
(Sigma-Aldrich) according to the manufacturer’s instruc-
tions. Briefly, 100 μg of semen exosome (SE) or blood
serum exosome (BE) in PBS was resuspended in 1 ml of
diluent C, mixed with freshly prepared PKH67 in diluent
C at a final concentration of 5 × 10-6 M and incubated
for 3 min. Labeling was stopped by addition of an equalvolume of exosome depleted FCS for 1 minute, followed by
ultracentrifugation for 30 min at 100,000 × g. After two
additional washes in PBS containing 10% exosome depleted
FCS, the exosomes were resuspended in 100 μl of PBS.
TZM-bL cells exposed to 100 μg/ml PKH67Green
labelled SE or BE for 3 h and 24 h were washed thrice in
PBS and collected using trypsin dissociation reagent
(Gibco). Cells were fixed for 15 min on ice with 2%
paraformaldehyde and fluorescence was analysed by use
of a FACSCalibur flow cytometer (BD) to detect the
PKH67Green transferred from exosomes to TZM-bl
cells during fusion and uptake. Cellular frequency and
fluorescence intensity were determined by Flowjo ana-
lysis software (TreeStar).
HIV-1 infection
Semen is the vector for sexual transmission of HIV-1,
and in an infected male, HIV-1 is expected to encounter
SE in the male genital tract (MGT). Therefore, SE or BE
(100 μg/mL) and HIV-1 (50 ng p24 antigen) were
co-incubated for 1 h at 37°C prior to addition to cell
cultures to mimic physiologic conditions in the MGT
unless otherwise stated. TZM-bl cells are a genetically
engineered HeLa cell line that expresses CD4, CXCR4
and CCR5 and contains HIV-1 Tat-inducible luciferase
and β–Gal reporter genes. The level of HIV-1 infection
was determined 24 h post viral challenge by resuspending
TZM-bl cells in Steady-Glo® luciferase substrate (Promega
Corporation) and measuring luminescence emission using
a luminometer. Infectivity readout was also assessed using
the Lentivirus-Associated p24 ELISA Kit (Cell Biolabs),
EnzChek® Reverse Transcriptase Assay Kit (Life Technolo-
gies Corporation), and RT-qPCR. Where indicated, HIV-1
target cells were pretreated with or without 10 nM AZT
for 2 h at 37°C prior to infection; and AZT was main-
tained for the duration of viral challenge. Viral input
was washed from cells thrice with PBS at 3 h post infec-
tion. For assessment of viral entry at 3 h post exposure
TZM-bL cell monolayers were washed thrice in PBS
and trypsinized (0.05%, Gibco) to efficiently dissociate
virus bound to the extracellular membrane [34] and to
dissociate the cells from the plate followed by three PBS
washing steps in a Eppendorf tubes at 300 × g for 5 m
to eliminate input virus that was not internalized. Cells
were then lysed with exosome free complete medium
containing 2% Triton-X 100 (Sigma-Aldrich) and pelleted
by centrifugation at 10,000 × g for 10 m. Supernatant was
collected and used to assay HIV internalization by p24
ELISA and RT activity.
LP-BM5 infection
Splenocytes obtained from healthy C57BL/6 mice were
plated at 1 × 105 in triplicates and infected with LP-BM5
that had been pre-incubated with PBS or SE (100 μg/mL)
Madison et al. Retrovirology 2014, 11:102 Page 13 of 15
http://www.retrovirology.com/content/11/1/102for 1 h at 37°C. Input virus was washed from cells thrice
with PBS at 3 h post infection. Ninety-six hours post viral
challenge, total DNA was extracted from cells and used
to evaluate viral load by quantitative PCR detection of
LP-BM5 proviral DNA.
HSV-1 and HSV-2 plaque reduction and single step
growth assays
For plaque reduction assay, 200,000 PFU of either HSV-1
(F) or HSV-2(G) [55] were incubated in 250 μl infection
medium (DMEM containing 1% heat inactivated calf
serum) with no exosomes (PBS vehicle), 100 μg/mL of BE
or 100 μg/mL of SE at 37°C for 1 hour. The volume of each
reaction was brought to 1 ml with infection medium, and
then serial ten-fold dilutions were prepared in infection
medium. Inocula containing 1 ml of the 10–1, 10–2, and
10–3 dilutions were plated onto confluent six-well cultures
of HEp-2 cells and incubated for 90 min at 37°C, after
which the inocula were replaced with infection medium
containing 1% methylcellulose. Plaques were allowed to
develop for two days at 37°C, and were then fixed,
immuno-stained and counted as previously described [56].
For the single-step growth assay, HEp-2 cells were pre-
incubated at 37°C for 1 hour with no exosomes (PBS
vehicle), 100 μg/mL of BE or 100 μg/mL of SE. HSV-1 or
HSV-2 (MOI = 5) was added to the cells and incubated for
1 hour at 37°C. Residual virus was removed by washing
with citrate buffer at pH =3.0 and cells were incubated for
18 hours to allow virus replication. Stocks were prepared
from each of the infected cultures by freeze-thaw and then
each stock was titered on Vero cells.
Statistical analysis
Statistical analysis of significant differences was tested
using paired, two-tailed Student’s t test. A p-value of ≤0.05
was regarded as statistically significant. Error bars repre-
sent standard deviations (SD).
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